The World Health Organisation (WHO) has approved a coronavirus vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI) for emergency use listing.
The WHO awarded the approval earlier on Tuesday based on the assessment given by the European Medicines Agency (EMA).
The new vaccine Nuvaxovid was developed by Novavax and the CEPI is the originator of the CovovaxTM vaccine that received WHO emergency use listing on December 17.
Both the coronavirus vaccines are made using similar technologies. Two doses of the vaccines are required for a patient and two to eight degree Celsius temperature is needed to keep the vaccine safe. Know also Moderna Says Covid-19 Booster dose works well.
The WHO’s experts on immunization of the Strategic Advisory Group has also issued the recommendations for NuvaxovidTM /CovovaxTM.
The approval for emergency use of the Nuvaxovid has been given when the rapidly transmissible variant, Omicron, spread in 90 countries across the world as of Tuesday.
The Emergency Use Listing (EUL) procedure has assessed the suitability of the products during the public health emergencies all over the world.
The Nuvaxovid is 90 percent effective in reducing symptomatic cases of coronavirus and the result came in two major clinical trials conducted in Britain, the United States and Mexico involving over 45,000 people, said the WHO.
The objective is to make vaccines, medicines and diagnostics of the coronavirus available as quick as possible to address the emergency and make people aware to adhering stringent criteria of safety, quality and efficacy. You can also know more about Biden Boosts Standards of Fuel-Economy.
As part of the EUL process, the company, producing the vaccine, must promise to continue generating data to ensure full licensure and WHO prequalification of the vaccine.
The WHO’s prequalification process will also evaluate the additional clinical data to be generated from the vaccine trials on a reeling basis to ensure the vaccine’s standards and quality, safety and efficacy for its availability in large scale.